Multiple Myeloma Posts - Page 3 of 26 on Medivizor
Navigation Menu

Multiple Myeloma Posts on Medivizor

Effectiveness of VCD-VTD therapy for older patients with newly diagnosed multiple myeloma.

Effectiveness of VCD-VTD therapy for older patients with newly diagnosed multiple myeloma.

Posted by on Sep 12, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study assessed the effects of administering personalized doses of VCD (bortezomib, cyclophosphamide, and dexamethasone) followed by VTD (bortezomib, thalidomide, and dexamethasone) in older patients with newly diagnosed multiple myeloma (NDMM). The data showed high response rates and safety in these patients. Some background...

Read More

Evaluating the effectiveness and safety of ciltacabtagene autoleucel for the treatment of patients with unresponsive multiple myeloma.

Evaluating the effectiveness and safety of ciltacabtagene autoleucel for the treatment of patients with unresponsive multiple myeloma.

Posted by on Aug 29, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the effectiveness and safety of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy for patients with previously treated relapsed or refractory (r/r) multiple myeloma (MM). The data showed that a single dose of cilta-cel was safe and effective for the treatment of these...

Read More

Adding isatuximab to carfilzomib and dexamethasone therapy for the treatment of relapsed multiple myeloma.

Adding isatuximab to carfilzomib and dexamethasone therapy for the treatment of relapsed multiple myeloma.

Posted by on Aug 22, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding isatuximab (Sarclisa) to carfilzomib (Kyprolis) and dexamethasone (Decadron) combination (Kd) for patients with previously treated relapsed multiple myeloma (MM). The data showed that adding isatuximab to the Kd regimen reduced the risk of disease progression or death for these...

Read More

How useful is a carfilzomib, bendamustine, and dexamethasone treatment combination for hard-to-treat multiple myeloma?

How useful is a carfilzomib, bendamustine, and dexamethasone treatment combination for hard-to-treat multiple myeloma?

Posted by on Aug 15, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study reported the safety and effectiveness of a combination of carfilzomib (Kyprolis), bendamustine (Treanda), and dexamethasone (Decadron) for patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that a combination of carfilzomib, bendamustine, and dexamethasone (CBd) showed promising...

Read More

Comparing the outcomes of proteasome inhibitors versus immunomodulators as maintenance therapy for patients with newly diagnosed multiple myeloma.

Comparing the outcomes of proteasome inhibitors versus immunomodulators as maintenance therapy for patients with newly diagnosed multiple myeloma.

Posted by on Aug 15, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study compared the outcomes of proteasome inhibitors (PIs) versus immunomodulators (IMs) as maintenance therapy for patients with newly diagnosed MM. The data showed that PIs maintenance increased the survival outcomes compared to IMs in these patients. Some background Multiple myeloma (MM) is a type of cancer that comes from blood...

Read More

Searching for patients with unresponsive multiple myeloma to trial an experimental treatment.

Searching for patients with unresponsive multiple myeloma to trial an experimental treatment.

Posted by on Aug 15, 2021 in Multiple Myeloma | 0 comments

In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including multiple myeloma (MM), that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment. This trial is...

Read More

Evaluating the long-term outcomes of ixazomib in combination with Rd for patients with relapsed or refractory multiple myeloma

Evaluating the long-term outcomes of ixazomib in combination with Rd for patients with relapsed or refractory multiple myeloma

Posted by on Aug 8, 2021 in Multiple Myeloma | 0 comments

In a nutshell This trial looked at the long-term effectiveness and safety of ixazomib (Ixa; Ninlaro) in combination with lenalidomide (R; Revlimid), and dexamethasone (d; Decadron) for the treatment of relapsed/refractory (RR) multiple myeloma (MM). The authors found that there was an improved survival with Ixa-Rd...

Read More

Significance of health related quality of life to confirm the benefits of D-VMP therapy in patients with newly diagnosed multiple myeloma

Significance of health related quality of life to confirm the benefits of D-VMP therapy in patients with newly diagnosed multiple myeloma

Posted by on Aug 7, 2021 in Multiple Myeloma | 0 comments

In a nutshell The study reports the outcomes of cancer treatment on the health-related quality of life (HRQoL) in patients with newly diagnosed multiple myeloma (MM) who were not eligible for a stem cell transplant (SCT). This study showed that treatment with VMP (bortezomib, melphalan, and prednisone) with or without daratumumab (Darzalex) improved...

Read More

Evaluating long-term outcomes of autologous SCT for patients with recurrent multiple myeloma

Evaluating long-term outcomes of autologous SCT for patients with recurrent multiple myeloma

Posted by on Aug 7, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the outcomes of autologous stem cell transplantation (ASCT) for patients with recurrent multiple myeloma (MM). This study found that long-term outcomes for these patients were promising, especially for patients who had the transplant right away after a first relapse. Some background Multiple myeloma (MM) is a type of...

Read More

Can flow cytometry predict multiple myeloma outcomes?

Can flow cytometry predict multiple myeloma outcomes?

Posted by on Aug 1, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study looked at how flow cytometry (FC) measurements predicted outcomes for patients with multiple myeloma (MM). It found that patients who had no traces of minimal residual disease (MRD) by FC had better outcomes. Some background Multiple myeloma (MM) is a blood cancer involving abnormal versions of plasma cells. Like plasma cells,...

Read More

Adding daratumumab to pomalidomide and dexamethasone therapy for treatment of relapsed/refractory multiple myeloma.

Adding daratumumab to pomalidomide and dexamethasone therapy for treatment of relapsed/refractory multiple myeloma.

Posted by on Jul 17, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding daratumumab (Darzalex) to pomalidomide (Pomalyst) and dexamethasone (Decadron) therapy for patients with previously treated relapsed or refractory (r/r) multiple myeloma (MM). The data showed that adding daratumumab to pomalidomide and dexamethasone regimen reduced the risk of...

Read More

Is Ixazomib, thalidomide and dexamethasone effective in treating relapsed and/or refractory multiple myeloma?

Is Ixazomib, thalidomide and dexamethasone effective in treating relapsed and/or refractory multiple myeloma?

Posted by on Jul 11, 2021 in Multiple Myeloma | 0 comments

In a nutshell This article looked at the effectiveness and safety of continuous ixazomib (Ninlaro), thalidomide (Thalomid), and dexamethasone (Decadron) (ITd) in the treatment of relapsed and/or refractory (RR) multiple myeloma (MM). The authors found that this regimen was well tolerated and showed promising effectiveness in the treatment of...

Read More